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Objective: No consensus exists on whether clozapine should be
prescribed in early stages of psychosis. This systematic review and meta-
analysis therefore focus on the use of clozapine as ﬁrst-line or second-
line treatment in non-treatment-resistant patients.
Methods: Articles were eligible if they investigated clozapine compared
to another antipsychotic as a ﬁrst- or second-line treatment in non-
treatment-resistant schizophrenia spectrum disorders (SCZ) patients
and provided data on treatment response. We performed random-
eﬀects meta-analyses.
Results: Fifteen articles were eligible for the systematic review (N = 314
subjects on clozapine and N = 800 on other antipsychotics). Our meta-
analysis comparing clozapine to a miscellaneous group of
antipsychotics revealed a signiﬁcant beneﬁt of clozapine (Hedges’
g = 0.220, P = 0.026, 95% CI = 0.026–0.414), with no evidence of
heterogeneity. In addition, a sensitivity analysis revealed a signiﬁcant
beneﬁt of clozapine over risperidone (Hedges’ g = 0.274, P = 0.030,
95% CI = 0.027–0.521).
Conclusion: The few eligible trials on this topic suggest that clozapine
may be more eﬀective than other antipsychotics when used as ﬁrst- or
second-line treatment. Only large clinical trials may comprehensively
probe disease stage-dependent superiority of clozapine and investigate
overall tolerability.
C. Okhuijsen-Pfeifer1,
E. A. H. Huijsman1, A. Hasan2,
I. E. C. Sommer3, S. Leucht4,
R. S. Kahn1,5, J. J. Luykx1,6,7,8
1Department of Psychiatry, Brain Center Rudolf Magnus,
University Medical Center Utrecht, Utrecht University,
Utrecht, The Netherlands, 2Department of Psychiatry and
Psychotherapy, Klinikum der Universit€at,, Munich,
Germany, 3Department of Neuroscience and Department
of Psychiatry, Universitair Medisch Centrum Groningen,
Groningen, The Netherlands, 4Department of Psychiatry
and Psychotherapy, Technische Universit€at M€unchen,
Munich, Germany, 5Department of Psychiatry, Icahn
School of Medicine at Mount Sinai, New York, NY,
USA, 6Department of Translational Neuroscience, Brain
Center Rudolf Magnus, University Medical Center
Utrecht, Utrecht University, Utrecht, The Netherlands,
7Department of Psychiatry, ZNA Hospitals, Antwerp,
Belgium and 8Department of Psychiatry,
SymforaMeander Hospital, Amersfoort, The Netherlands
This is an open access article under the terms of the
Creative Commons Attribution-NonCommercial License,
which permits use, distribution and reproduction in any
medium, provided the original work is properly cited and
is not used for commercial purposes.
Key words: schizophrenia; first-episode; antipsychotics;
meta-analysis
Jurjen Luykx, Psychiatrist and Head of Program in
Psychiatric Genetics, Human Neurogenetics Unit, Brain
Center Rudolf Magnus, University Medical Center
Utrecht, Universiteitsweg 100, office 4.127 (Stratenum),
HP 4.205, 3584 CG Utrecht, The Netherlands.
E-mail: j.luykx@umcutrecht.nl
Accepted for publication August 6, 2018
Summations
• As a ﬁrst- or second-line treatment option clozapine outperforms other antipsychotics in schizophrenia spectrum disorders.
• Compared to ﬁrst-line risperidone, clozapine is more eﬀective in schizophrenia spectrum disorders.
Considerations
• Few studies have studied clozapine as a ﬁrst- or second-line treatment modality in schizophrenia spectrum disorders.
• When including only randomized controlled trials, beneﬁcial eﬀects of clozapine over other antipsychotic drugs become
insigniﬁcant, although the direction of eﬀect (clozapine outperforming other antipsychotics) remains unchanged.
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In most countries, clozapine (CLZ) is the only regis-
tered drug for treatment-resistant schizophrenia
(TRS). CLZ is also known to be one of the most
eﬀective antipsychotic agents (1–4). Up to 30% of
TRS patients receive CLZ (5). CLZ is prescribed late
in the course of illness (6), with an estimated time
lag of ≥5 years (7). This delay may worsen outcome
as increasing numbers of exacerbations of psychotic
symptoms impair daily functioning (8–10). The
ongoing debate about when to initiate CLZ could
possibly explain the current underutilization.
A number of approaches have been applied in dif-
ferent study designs to investigate CLZ’s superiority
to other antipsychotics. In two observational stud-
ies, one in TRS and non-TRS patients (11) and the
other in TRS patients only (12), improved treatment
adherence for CLZ relative to other antipsychotics
was demonstrated. Three randomized controlled tri-
als in TRS patients point to better eﬃcacy for CLZ
(13–15), as well as better treatment adherence (14,
15), relative to other antipsychotics except for olan-
zapine (15). In four meta-analyses, two in TRS only
(16, 17) and two in TRS and non-TRS patients (18,
19), CLZ performed better than other antipsychotics
except for haloperidol (17), second-generation
antipsychotics as a group (17), risperidone (19), and
zotepine (19). A Cochrane review (including its later
update) in TRS and non-TRS patients concluded
that CLZ is more eﬃcacious than ﬁrst-generation
antipsychotics, and the diﬀerence in eﬃcacy com-
pared to other antipsychotics turned out to be larger
for TRS patients than for non-TRS patients (20,
21). In summary, previous ﬁndings regarding CLZ’s
eﬃcacy compared to other antipsychotics are incon-
sistent. This could be explained by variable primary
outcomes used in these trials, variable treatment
designs, variable active comparators, variable dis-
ease stages studied, and by potential funding bias
(16).
One may posit that CLZ works better when used
earlier in the disease (8–10). This was investigated
with a randomized treatment algorithm in early
TRS patients (22–25). The results indicate that using
CLZ early in treatment was eﬀective (22–25). Meta-
analyses on the same dataset demonstrate similar
eﬃcacy proﬁles across antipsychotics in ﬁrst-episode
psychosis (26, 27). However, it is currently unknown
whether the eﬃcacy of CLZ vs. other antipsychotics
depends on stage of the disease.
Aims of the study
Improving insight into the eﬃcacy of CLZ in ear-
lier disease stages than third-line may help
clinicians balancing CLZ’s serious adverse reac-
tions with its potential beneﬁts in early disease
stages. We therefore set out to systematically
review and meta-analyze response to CLZ when
used as a ﬁrst- or second-line treatment in non-
TRS SCZ patients.
Methods
We performed a literature search to identify all
observational and interventional studies and case
reports published until January 1, 2018, investigat-
ing the eﬀect of CLZ on treatment response as a
ﬁrst- or second-line treatment in SCZ patients.
This systematic review was conducted in accor-
dance with the Preferred Reporting Items for Sys-
tematic Reviews and Meta-analyses (PRISMA)
standards, except for prepublication of our
protocol (28).
Inclusion and exclusion criteria
Studies were included in the systematic review if
they: (i) investigated CLZ; (ii) included only adult
human participants (≥18 years, with no upper age
limit) with a diagnosis of schizophrenia, schizoaf-
fective disorder, schizophreniform disorder, or
psychosis not otherwise speciﬁed (clinician-based
and/or using (semi-)structured interviews); (iii)
investigated CLZ as a ﬁrst-line or second-line
treatment (so in non-treatment-resistant patients,
who are generally deﬁned as being refractory to at
least two antipsychotics); (iv) had been written in
English; and (v) when the full text was available.
When a full text of an article was not available
through our university library, librarians tried to
retrieve the article from other sources, and the
authors were contacted twice to request the arti-
cles. Controlled and non-controlled studies, as well
as narrative reviews and case reports, were
included. We excluded articles related to CLZ if
the study population concerned TRS SCZ patients
in whom CLZ was not used as a ﬁrst- or second-
line treatment or when no data were available
about treatment response (deﬁned as data on posi-
tive, negative, or total symptoms, for example,
Positive and Negative Syndrome Scale (PANSS),
Brief Psychiatric Rating Scale (BPRS), or Clinical
Global Impression (CGI) data).
Resources and searches
Two independent reviewers (CP and EH) per-
formed electronic searches using PubMed,
EMBASE, Cochrane Central, and PsycINFO
until January 1, 2018. The following search
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terms were used: ‘Clozapine’ AND ‘schizophre-
nia spectrum and other psychotic disorders’ OR
‘schizophreni*’ OR ‘psychotic’ OR ‘psychosis’
OR ‘psychoses’ AND ‘naive’ OR ‘ﬁrst response’
OR ‘ﬁrst line’ OR ‘ﬁrst treatment’ OR ‘second
treatment’ OR ‘ﬁrst episode’ OR ‘second line’.
In addition, the reference lists of the retrieved
articles and relevant review articles were screened
for possible additional, eligible articles. Last,
searches were done in www.clinicaltrials.gov and
www.who.int/trialsearch to ﬁnd additional (on-
going) trials. We thus identiﬁed two possibly rel-
evant trials, but their results had not been
published. The full search strings can be found
in the Appendix S1.
Study selection
Abstracts of all articles identiﬁed by our search
were independently examined by two of the
authors (CP and EH); whenever eligibility was not
clearly described in the abstract, full texts were
examined. The lists of articles retrieved by the two
authors were compared. Discrepancies were
resolved during consensus meetings.
Meta-analysis
The selected articles were screened for eligibility
for meta-analysis. The primary outcome was treat-
ment response on CLZ vs. any other antipsychotic,
as deﬁned by the authors in changes in positive,
negative, or total symptoms on the PANSS, BPRS,
or CGI. In most of the studies included in this sys-
tematic review, response was deﬁned as 50%
change on BPRS (3, 29, 30), while other studies
(also) deﬁned response as a CGI of ‘mild’ or less
(3, 29–32). One study used the Schedule for Aﬀec-
tive Disorders and Schizophrenia – change
(SADS-C) version to identify treatment response
(32). Case reports were excluded for the meta-ana-
lysis part of the study, as well as articles without
data on treatment response. Our ﬁrst aim was to
analyze CLZ vs. other antipsychotics. Only in the
event three or more studies reported on outcomes
in CLZ users vs. a speciﬁc active comparator, a
sensitivity meta-analysis was planned. We identi-
ﬁed articles including study populations overlap-
ping with other studies by checking descriptions of
study populations, author names, article titles, and
cross-references. In such instances of overlapping
study populations, the article with the highest
quality score was selected, while the other was
excluded. The quality of the articles was assessed
using the CONSORT quality checklist (33). The
meta-analysis test statistics were generated with
the program ‘Comprehensive meta-analysis’ ver-
sion 2.2.064 (2011) from BioStat. A random-eﬀects
model was used with alpha set at 0.05. Heterogene-
ity was tested using a homogeneity test (Cochran’s
Q test) and the I2 statistic (34), with the absence of
heterogeneity deﬁned as I2 = 0.00, while I2 values
of 0.25, 0.50, and 0.75 were considered indicative
of low, moderate, and high degrees of heterogene-
ity. Publication bias was assessed using funnel
plots.
Results
Studies included in the systematic review
Using our search methods, 1248 articles were
found. Applying our inclusion and exclusion crite-
ria reduced the number of relevant articles to ﬁf-
teen (3, 29–32, 35–44), ten of which evaluated CLZ
as a ﬁrst-line treatment (3, 29, 31, 32, 35–40), while
ﬁve were clinical reports that evaluated CLZ as a
second-line treatment (Fig. 1) (30, 41–44). It is
important to note that, from the articles excluded
on the basis of criterion d1, nine articles (all pub-
lished before 1990) seemed eligible at ﬁrst sight
because they investigated CLZ use in acutely psy-
chotic patients (Fig. 1) (45–53). However, no
information was available on whether they were
ﬁrst-episode patients or previous antipsychotic
users.
Systematic review – Clozapine as a first-line treatment
There were two case reports (39, 40) and eight tri-
als (3, 29, 32, 35–38) investigating CLZ as a ﬁrst-
line treatment. Detailed information about the
outcomes mentioned in these papers can be found
in the Supplementary Results. Both case reports
concluded CLZ was eﬀective (there was no active
comparator). Four trials (50%) provided summary
statistics in line with CLZ being equally eﬀective
to other antipsychotics (3, 29, 31, 32), while four
trials (50%) pointed to increased eﬃcacy of CLZ
over other antipsychotics (35–38).
Systematic review – Clozapine as a second-line treatment
There were four case reports (41–44) and one
trial investigating CLZ as a second-line treatment
(30). Detailed information about the outcomes
mentioned in these papers can be found in the
Supplementary Results. All four case reports
concluded CLZ was eﬀective (there was no active
comparator). The only trial that could be
included also pointed to increased eﬃcacy of
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CLZ over other antipsychotics. A more detailed
overview can be found in the Supplementary
Results.
Meta-analyses
Fifteen articles were screened. Six case reports (39–
44), two articles with overlapping study popula-
tions (29, 36), and two articles without data to
analyze/no active comparator (32, 38) were
excluded. From the ﬁve articles that remained,
three compared clozapine vs. risperidone (31, 35,
37), one compared clozapine vs. chlorpromazine
(3), and one compared clozapine vs. thioridazine
(30). An overview of the studies can be found in
Table 1.
The ﬁrst meta-analysis was performed to assess
whether CLZ as a ﬁrst- or second-line treatment
has a beneﬁt over a miscellaneous group of
antipsychotics. This analysis revealed a signiﬁcant
beneﬁt of CLZ over other antipsychotics (Hedges’
g = 0.220, P = 0.026, CI = 0.026–0.414; Fig. 2a),
with no evidence of heterogeneity (Q = 2.118,
I2 = 0.00). Inspection of the funnel plot did not
give rise to suspicion of publication bias, although
the numbers of studies were too low for thorough
assessments because this method is based on sym-
metry (Figure S2a).
Then, a sensitivity meta-analysis was performed
on CLZ vs. risperidone (RISP) as this antipsy-
chotic was most often compared with CLZ. All
these data concerned CLZ vs. RISP as a ﬁrst-line
treatment. This meta-analysis revealed a signiﬁcant
beneﬁt of CLZ over RISP (Hedges’ g = 0.274,
P = 0.030, CI = 0.027–0.521; Fig. 2b), with no evi-
dence of heterogeneity (Q = 0.472, I2 = 0.00).
Inspection of the funnel plot did not give rise to
suspicion of publication bias, although the number
of studies was low (Figure S2b).
We found that two studies (31, 37) included in
our meta-analysis were naturalistic. Another sensi-
tivity analysis was therefore performed on CLZ vs.
other antipsychotics only including randomized
controlled trials (3, 30, 35), revealing no signiﬁcant
beneﬁt of CLZ over the other antipsychotics
(Hedges’ g = 0.169, P = 0.271, CI = 0.131–
0.468; Figure S3, with no evidence of heterogene-
ity, Q = 1.729, I2 = 0.00). Another sensitivity
EMBASE
Fig. 1. Flow diagram of the systematic




analysis only including blinded RCTs (3, 30) did
not reveal a signiﬁcant beneﬁt of CLZ over the
other antipsychotics either (Hedges’ g = 0.159,
P = 0.411, CI = 0.219–0.537; Figure S4). How-
ever, the directions of eﬀect remained identical for
all these sensitivity analyses, favoring CLZ.
Discussion
Despite a scarcity of studies on this topic, we found
increased eﬃcacy of clozapine as a ﬁrst- or second-
line treatment in schizophrenia spectrum patients
compared to other antipsychotic medication, in
particular, relative to risperidone. This ﬁnding sug-
gests that CLZ might be superior to other antipsy-
chotics when used earlier than as a third step.
However, our study was not designed to investigate
CLZ’s overall tolerability, and therefore, we can-
not recommend it as a ﬁrst-line treatment for SCZ.
On the other hand, our ﬁndings may contribute to
recent recommendations of CLZ as a second-line
treatment in certain SCZ patients (54).
Table 1. Summary of study characteristics
Study AP line Comp. AP Outcome Duration (weeks)
Mean CLZ dose
(mg/day)
Mean Comp. AP dose
(mg/day) Result N CLZ N total
Lieberman et al. (2003) (3) 1st CPZ BPRS 52 300* 400* # 68 130
Sanz-Fuentenebro et al. (2013) (35) 1st RISP PANSS 52 220.45 5.43 + 9 14
Sahni et al. (2016) (37) 1st RISP PANSS 26 289.28 6.85 + 28 55
Zhang et al. (2016) (31) 1st RISP PANSS 52 Data missing Data missing # 84 183
Edwards et al. (2011) (30) 2nd THR CGI 24 364.65 148.55 # 14 25
Total 203 407
AP line, use of CLZ as a first- (‘1st’) or second-line (‘2nd’) antipsychotic; Comp. AP, comparator antipsychotic; CPZ, chlorpromazine; RISP, risperidone; THR, thioridazine; PANSS,
Positive and Negative Syndrome Scale; CGI, Clinical Global Impression; N CLZ, Number of patients on clozapine; N total, Number of patients on CLZ and on Comp; AP, ‘+’ = fa-
voring CLZ; ‘#’ = CLZ equally effective as Comp; AP, *median dose.
Fig. 2. (a) Forest plot showing meta-analytic results of response to clozapine vs. other antipsychotics. Squares (whiskers represent
95% conﬁdence intervals) indicate the eﬀect sizes of the individual studies. The size of the squares reﬂects the sample size of each
individual study. Diamonds represent summary statistics. CI, conﬁdence interval; other AP, risperidone/chlorpromazine/thiori-
dazine; CLZ, clozapine. (b) Forest plot showing meta-analytic results of response to clozapine vs. risperidone. Squares (whiskers rep-
resent 95% conﬁdence intervals) indicate the eﬀect sizes of the individual studies. The size of the squares reﬂects the sample size of
each individual study. Diamonds represent summary statistics. CI, conﬁdence interval; RISP, risperidone; CLZ, clozapine. [Colour
ﬁgure can be viewed at wileyonlinelibrary.com]
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To our knowledge, the current study is the
ﬁrst systematic review and meta-analysis com-
prehensively probing the use of CLZ in early
disease stages. Relatively high eﬃcacy of CLZ
may stem from its important eﬀects on psy-
chotic features. However, as the main outcome
was general improvement on total PANSS,
BPRS, or GCI measures, other aspects of CLZ
– such as its beneﬁcial eﬀects on aggressive
behavior (55), suicidality (56), and substance
abuse (57) – may also have contributed. In clin-
ical settings, the decision to start a speciﬁc
antipsychotic is not only based on eﬃcacy, but
also on tolerability and safety, which may be
lower for CLZ compared to other antipsy-
chotics. Nevertheless, lower mortality rates have
been found in CLZ users compared to all other
antipsychotics (58, 59) and compared to former
CLZ users (60) and to users of other antipsy-
chotics (59), suggesting long-term good physical
tolerability of CLZ. Another factor possibly
explaining our results is that patient characteris-
tics independent of disease stage may partially
explain CLZ treatment response: Some research
hints that factors such as abundant negative
symptoms, a longer duration of untreated psy-
chosis (61), young age at onset (61, 62), and
disorganized subtype of SCZ (63) might predict
TRS early in the disease.
The prime limitation of our method is the rela-
tive paucity of available studies comparing CLZ to
active comparators in early disease stages, likely
explaining the non-signiﬁcant results when consid-
ering only RCTs or blinded RCTs. However, our
inclusion of naturalistic studies in the main analy-
sis has most likely resulted in conservative esti-
mates of CLZ’s eﬃcacy as CLZ may be preferred
for patients with relatively severe symptomatology
compared to other antipsychotics, who in turn
may be more diﬃcult to treat. Alternatively, one
may reason that, in treatment-compliant patients,
CLZ may be preferred over depot antipsychotics
since CLZ is unavailable as long-acting injectable
and CLZ requires mandatory blood tests. This
could in turn have resulted in overestimated eﬀect
sizes of CLZ vs. other antipsychotics. In addition,
although the eﬀect sizes we found in our meta-ana-
lyses were relatively small (0.155–0.546), possibly
such eﬀect sizes may reﬂect a proportion of
patients responding well (e.g., hedge’s g = 0.5),
while some receiving CLZ in early disease stages
may respond more poorly (e.g., hedge’s g = 0.05).
The fairly large standard deviations for treatment
response found in the studies we base our meta-
analysis on (31, 35, 37) hints at variable response
rates on CLZ in early disease stages. Furthermore,
our observation that the directions of eﬀect in all
sensitivity analyses do not change compared to our
main analysis may be indicative of lack of power
rather than lack of beneﬁt of CLZ. On a general
note, the relative scarcity of studies limits statisti-
cal power and extrapolation to other active com-
parators than risperidone. A potential caveat of
two studies (6, 57) is their use of baseline data
including subjects lost to follow-up. However, con-
sidering the absence of heterogeneity and the over-
all identical eﬀect sizes between the studies
included in our meta-analysis, it is unlikely that
such participants have inﬂuenced the results.
Moreover, in our analyses, lower sample sizes
excluding drop-outs were used, likely rendering
our method relatively conservative.
Future, large, randomized controlled clinical
trials may elucidate whether prescribing CLZ as a
ﬁrst- or second-line treatment to patients with
schizophrenia spectrum disorders may indeed
improve compliance, quality of life, and treatment
response. Such trials may also shed light on
patient characteristics associated with CLZ eﬃ-
cacy in variable disease stages and should also
consider CLZ’s safety proﬁle relative to other
antipsychotics.
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regarding meta-analysis 1.
Figure S3. Forest plot showing meta-analytic results of
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